Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with...
May 11, 2023 16:05 ET | Source: Rain Oncology Inc.

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2...
April 24, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Report First Quarter 2023 Financial Results and Highlights Recent Progress on May 11, 2023

NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
April 05, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023

NEWARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
March 21, 2023 05:50 ET | Source: Rain Oncology Inc.

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
March 09, 2023 16:05 ET | Source: Rain Oncology Inc.

Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2...
March 07, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
February 23, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
February 09, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit

NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
January 31, 2023 16:27 ET | Source: Rain Oncology Inc.

UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9,...